ＪＣＲファーマ（4552） – Notice Regarding Nomination of Candidates for New Members of the Board of Directors

News Release April 27, 2022 JCR Pharmaceuticals Co., Ltd. Translation Notice Regarding Nomination of Candidates for New Members of the Board of Directors Apr. 27, 2022 — JCR Pharmaceuticals Co., Ltd. (TSE 4552; Chairman and President: Shin Ashida; “JCR”) announced that its Board of Directors resolved at a meeting held today to submit a proposal regarding nomination of a candidate for the Board of Directors to be presented before JCR’s Ordinary General Meeting of Shareholders scheduled in June, 2022. The appointment of the new Members of the Board will be subject to approval at the Ordinary General Meeting of Shareholders. 1. Candidates for New Directors Name Career Yutaka Atomi, M.D., Ph.D. Apr. 1970 Attending Surgeon, First Department of Surgery, Faculty of Medicine, The University of Tokyo Apr. 1982 Chief of Medical Staff, First Department of Surgery, Faculty of Medicine, The University of Tokyo Jun. 1988 Visiting Researcher, Department of Surgery, University of California, San Francisco J ul. 199 2 Assistant Professor, First Department of Surgery, Faculty of Medicine, The University of Tokyo Oct. 1992 Professor, First Department of Surgery, Faculty of Medicine, Kyorin University Apr. 2004 Dean, School of Medicine, Kyorin University Apr. 2010 President, Kyorin University Jun. 2013 Outside Audit & Supervisory Board Member, Sumitomo Dainippon Pharma Co., Ltd. (currently Sumitomo Pharma Co., Ltd.) Jun. 2017 Outside Director, Sumitomo Dainippon Pharma Co., Ltd. (currently Sumitomo Pharma Co., Ltd.) (current) Apr. 2018 President Emeritus, Kyorin University (current) Jun. 2018 President, Pancreas Research Foundation of Japan Apr. 2019 President, International Medical Research Foundation (current) Jun. 2019 Outside Audit & Supervisory Board Member, Sanki Engineering Co., Ltd. (current) Name Career Philippe Fauchet OBE Oct. 1984 Entered Roussel UCLAF S.A., France Sep. 1996 Entered Sanofi S. A. Jun. 2001 Appointed President and Representative Director, Sanofi-Synthelabo K.K. (currently Sanofi K.K) May 2005 Appointed President and Representative Director, Sanofi-Aventis K.K. (currently Sanofi K.K) Jan. 2010 Appointed President and Representative Director, GlaxoSmithKline K.K. Jun. 2013 Appointed Director, JCR Pharmaceuticals Co., Ltd. Apr. 2017 Appointed Chairman and Representative Director, GlaxoSmithKline K.K. Nov. 2017 Resigned as Director, JCR Pharmaceuticals Co., Ltd. Feb. 2019 Stepped down as Chairman, GlaxoSmithKline K.K. May 2019 External Director, Bonac Corporation (current) Mar. 2020 External Director, Noile-Immune Biotech Inc. (current) Sep. 2020 External Director, Rezolute, Inc.(RZLT) (current) About JCR Pharmaceuticals Co., Ltd. JCR Pharmaceuticals Co., Ltd. (TSE 4552) is a global specialty pharmaceuticals company that is redefining expectations and expanding possibilities for people with rare and genetic diseases worldwide. We continue to build upon our 46-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. We improve patients’ lives by applying our scientific expertise and unique technologies to research, develop, and deliver next-generation therapies. Our approved products in Japan include therapies for the treatment of growth disorder, Fabry disease, MPS II (Hunter syndrome), acute graft-versus host disease, and renal anemia. Our investigational products in development worldwide are aimed at treating rare diseases including MPS I (Hurler, Hurler-Scheie and Scheie syndrome), Hunter syndrome, MPS IIIA and B (Sanfilippo disease), Pompe disease, and more. JCR strives to expand the possibilities for patients while accelerating medical advancement at a global level. Our core values – reliability, confidence, and persistence – benefit all our stakeholders, including employees, partners, and Together we soar. For more information, please visit https://www.jcrpharm.co.jp/en/site/en/. patients. Cautionary Statement Regarding Forward-Looking Statements This document contains forward-looking statements that are subject to known and unknown risks and uncertainties, many of which are outside our control. Forward-looking statements often contain words such as “believe,” “estimate,” “anticipate,” “intend,” “plan,” “will,” “would,” “target” and similar references to future periods. All forward-looking statements regarding our plans, outlook, strategy and future business, financial performance and financial condition are based on judgments derived from the information available to us at this time. Factors or events that could cause our actual results to be materially different from those expressed in our forward-looking statements include, but are not limited to, a deterioration of economic conditions, a change in the legal or governmental system, a delay in launching a new product, impact on competitors’ pricing and product strategies, a decline in marketing capabilities relating to our products, manufacturing difficulties or delays, an infringement of our intellectual property rights, an adverse court decision in a significant lawsuit and regulatory actions. This document involves information on pharmaceutical products (including those under development). However, it is not intended for advertising or providing medical advice. Furthermore, it is intended to provide information on our company and businesses and not to solicit investment in securities we issue. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the factors that could cause actual results to differ materially, even if new information becomes available in the future. Contact: Investors & Media: JCR Pharmaceuticals Co., Ltd. Corporate Communications ir-info@jcrpharm.co.jp